pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,007 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1878Endpoints1458Fierce Biotech772BioSpace762BioPharma Dive551raps249onclive165fda recalls
therapy area
allOncology12974Rare Disease3368Immunology3056Cardiology2860Hematology2314Pulmonology2256Vaccines
  • Congressional biotech panel cautions on rising China licensing deals
    A bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…
    Endpoints · 3h agoRegulatoryNegative↗ source
  • Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher disease
    Sanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
    Endpoints · 4h agoApprovalPositive↗ source
← prev
page 1 of 161
next →
122
fda medwatch116
globenewswire health73
fda press62
1861
Psychiatry & CNS1235
Ophthalmology1140
Endocrinology & Metabolism809
Pain793
Nephrology788
  • Sanofi explores acquisition of Insmed in potential major biopharma deal
    Sanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
    Endpoints · 7h agoDealNeutral↗ source
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 9h agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 10h agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 11h agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 16h agoDealPositive↗ source
  • U.S. loses measles elimination status as outbreaks claim first deaths in decades
    The Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…
    STAT · 43m agoNegative↗ source
  • Study finds malaria antibody L9LS reduces vaccine response in infants
    Researchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
    STAT · 1h agoNegative readoutNegative↗ source
  • Eli Lilly breaks ground on $3.5 billion Pennsylvania plant to produce obesity drugs
    Eli Lilly has begun construction of a new manufacturing facility in the Lehigh Valley region of Pennsylvania. The $3.5 billion plant is slated to increase capacity for the company’s obesity drug po…
    Endpoints · 6h agoNeutral↗ source
  • Lawmakers push for stronger U.S. biotech support to stay ahead of China
    Members of the congressional Biotech Caucus told reporters that Washington must act quickly to boost the U.S. biotech sector and keep it ahead of China. They called for increased funding, streamli…
    STAT · 6h agoRegulatoryNeutral↗ source
  • Telehealth firms Hims & Hers and Noom launch prescription peptide programs after HHS rule change
    Telehealth companies Hims & Hers and Noom announced this week that they will begin prescribing peptide products to eligible patients, marking the first major consumer‑focused rollouts of such thera…
    STAT · 6h agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 6h agoDealPositive↗ source
  • Oura announces acquisition of Counsel Health at HLTH conference
    Oura, known for its wearable health tracker, disclosed that it is purchasing Counsel Health, a company that provides health data services. The announcement was made during the HLTH conference, whe…
    Endpoints · 7h agoDealPositive↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 8h agoPositive readoutNeutral↗ source
  • Grand Strand Sandwich Co. recalls four Lunch Box sandwich products over Listeria risk
    Grand Strand Sandwich Company Inc. announced a recall of four Lunch Box sandwich items because they may be contaminated with Listeria monocytogenes. The recalled products are the Chicken Sausage B…
    fda recalls · 18h agoCRLNegative↗ source
  • Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosis
    Eli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…
    Endpoints · 9h agoPositive↗ source
  • National Academies urges faster retractions and corrections to protect scientific record
    The National Academies of Sciences, Engineering, and Medicine released a report urging the scientific community to act more quickly when errors or data manipulation are identified in published rese…
    STAT · 7h agoPositive↗ source
  • MAHA PAC spent more on its own D.C. steakhouse events than on a key ally’s House race before midterm losses
    The political arm of Make America Healthy Again (MAHA) directed millions of dollars to its own operations, including a high‑profile dinner in Washington, D.C., rather than funneling that money to c…
    STAT · 14h agoNegative↗ source
  • Sanders says expanded Medicare plan may still pass despite Trump’s potential veto
    Senator Bernie Sanders told reporters that he is not certain a Trump veto would block an expanded Medicare for All proposal, suggesting the legislation could still move forward. The proposal appea…
    STAT · 10h agoNeutral↗ source
  • Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese data
    Erasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…
    STAT · 12h agoNeutral↗ source
  • Study finds stopping statins in older adults may lead to worse outcomes despite non-inferior label
    A new trial called STREAM examined whether older adults without prior heart attacks or strokes could safely stop taking statins. The study was presented at the American Heart Association annual mee…
    STAT · 14h agoNegative readoutNeutral↗ source
  • MAHA PAC’s spending favors allies over its own candidates, raising questions about strategy
    Recent filings reveal that the MAHA political action committee directed a sizable portion of its money toward allied groups, boosters and an affiliated nonprofit rather than directly funding its ow…
    STAT · 7h agoNegative↗ source
  • STAT+: Epic defends competitive practices; promises AI access to records
    In this edition of STAT Health Tech: EHR giant, Epic defends its competitive tactics, new data on AI and health care costs, and HLTH news.
    STAT · 9h ago↗ source
  • FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
    The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
    fda press · 1d agoApprovalPositive↗ source